BioNTech (NASDAQ:BNTX) Sees Large Volume Increase – Here’s Why

BioNTech SE (NASDAQ:BNTX) shares saw an uptick in trading volume on Tuesday . 254,365 shares traded hands during trading, a decline of 46% from the previous session’s volume of 469,307 shares.The stock last traded at $127.06 and had previously closed at $120.21.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BNTX shares. Deutsche Bank Aktiengesellschaft increased their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Canaccord Genuity Group boosted their price target on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. Finally, HSBC upped their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.76.

BioNTech Stock Performance

The stock has a market cap of $29.28 billion, a P/E ratio of -58.17 and a beta of 0.18. The stock has a fifty day simple moving average of $113.89 and a 200-day simple moving average of $102.93. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.73 earnings per share. Equities analysts expect that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares during the period. Blue Trust Inc. grew its holdings in shares of BioNTech by 491.1% during the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares in the last quarter. TD Asset Management Inc raised its position in BioNTech by 6.1% in the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after buying an additional 435 shares during the last quarter. Planning Capital Management Corp lifted its stake in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in BioNTech by 17.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company’s stock worth $465,000 after acquiring an additional 582 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.